In this composite image, a human nerve cell derived from a patient with Rett syndrome shows significantly decreased levels of KCC2 compared to a control cell.
Image: Gong Chen lab, Penn State University
Penn State scientists have discovered a novel drug target and have rescued functional deficits in human nerve cells derived from patients with Rett Syndrome, a severe form of autism-spectrum disorder. The research, led by Gong Chen, professor of biology and the Verne M. Willaman Chair in Life Sciences at Penn State, could lead to a new treatment for Rett Syndrome and other forms of autism-spectrum disorders. A paper describing the research was published on Jan. 4, 2016, in the online Early Edition of the journal Proceedings of the National Academy of Sciences.
“The most exciting part of this research is that it directly uses human neurons that originated from Rett Syndrome patients as a clinically-relevant disease model to investigate the underlying mechanism,” said Chen. “Therefore, the new drug target discovered in this study might have direct clinical implication in the treatment of Rett Syndrome and potentially for other autism-spectrum disorders as well.”
The researchers differentiated stem cells derived from the skin cells of patients with Rett Syndrome into nerve cells that could be studied in the laboratory. These nerve cells carry a mutation in the gene MECP2, and such gene mutations are believed to be the cause of most cases of Rett Syndrome. The researchers discovered that these nerve cells lacked an important molecule, KCC2, that is critical to normal nerve cell function and brain development.
“KCC2 controls the function of the neurotransmitter GABA at a critical time during early brain development,” Chen said. “Interestingly, when we put KCC2 back into Rett neurons, the GABA function returns to normal. We therefore think that increasing KCC2 function in individuals with Rett Syndrome may lead to a potential new treatment.”
The researchers also showed that treating diseased nerve cells with insulin-like growth factor 1 (IGF1) elevated the level of KCC2 and corrected the function of the GABA neurotransmitter. IGF1 is a molecule that has been shown to alleviate symptoms in a mouse model of Rett Syndrome and is the subject of an ongoing phase-2 clinical trial for the treatment of the disease in humans.
“The finding that IGF1 can rescue the impaired KCC2 level in Rett neurons is important not only because it provides an explanation for the action of IGF1,” said Xin Tang, a graduate student in Chen’s Lab and the first-listed author of the paper, “but also because it opens the possibility of finding more small molecules that can act on KCC2 to treat Rett syndrome and other autism spectrum disorders.”
Read more: Discovery of a new drug target could lead to novel treatment for severe autism
The Latest on: Autism-spectrum disorder
via Google News
The Latest on: Autism-spectrum disorder
- Sibling's likelihood of autism diagnosis impacted by age gap, study findson August 25, 2021 at 9:22 am
Mothers of children with autism who delayed their subsequent pregnancy by 2.5 to three years reduced the likelihood of their next child also being diagnosed on the spectrum, new research shows.
- I'm A Woman Who Was Diagnosed With Autism At 44on August 25, 2021 at 6:03 am
The panel of clinicians who’d assessed me were experts in their field: autism spectrum disorder. At the word “disorder,” I bristled. The doctor asked if I’d found the process stressful, and I nodded.
- Sibling's likelihood of autism diagnosis impacted by age gapon August 25, 2021 at 4:00 am
Mothers of children with autism who delayed their subsequent pregnancy by 2.5 to three years reduced the likelihood of their next child also being diagnosed on the spectrum, new research shows.
- Understanding motor problems in children with autism spectrum disorderon August 24, 2021 at 8:19 am
Anjana Bhat, associate professor in the University of Delaware’s Department of Physical Therapy, has been awarded a research project (R01) grant through the National Institutes of Health for the next ...
- International Consortium for Health Outcomes Measurement launches the first-ever global standard set to enhance care for Autism Spectrum Disorderon August 24, 2021 at 4:04 am
Standardized set completed in collaboration with various autism service and healthcare providersBoston, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The International Consortium for Health Outcomes Measurement ...
- Cambridge University launches UK's largest ever autism study as 10,000 people are recruited to look at how disorder developson August 24, 2021 at 3:08 am
Researchers from the University of Cambridge have launched a study of 10,000 people with autism to examine the role genetic and environmental factors play in placing people on the spectrum.
- What to know about autism discrimination in the workplaceon August 23, 2021 at 11:00 pm
Despite improvements in general awareness, many individuals still face autism discrimination in the workplace. Learn more.
- New nonprofit employs people on Autism Spectrumon August 23, 2021 at 6:38 am
Spectrum Studios is employing people on the Autism Spectrum. They are helping create job opportunities for people in our community.
- Before her incest charge, Chris Chan was trolled for years. Experts say her reported autism spectrum disorder made her an easy target for harassment.on August 19, 2021 at 9:56 am
After being charged with incest, Christine Chandler's lawyer said her engagement with online trolls was linked to her mental state and disability.
- Autism Spectrum Disorder Market 2021 Situation Focussing on Key Drivers & Growth by 2028, Key Players -Behavior Innovations, and Hopebridge, LLC.on August 18, 2021 at 8:00 am
Decisive Markets Insights has published a new report on xx market today for companies like yourselves so that you gain the maximum traction from the precise projections and accurate Atrophic Vaginitis ...
via Bing News
